Citius Pharmaceuticals, Inc. — FY2016 Form 10-K
Business context and reporting period. This 10-K covers the fiscal year ended September 30, 2016; it is not a report for calendar Q4 2016. Citius is a clinical-stage specialty pharmaceutical company with no reported revenue. Following its March 2016 acquisition of Leonard-Meron Biosciences (LMB), its principal programs were Mino-Lok, an antibiotic catheter-lock treatment, and Hydro-Lido, a topical hemorrhoid treatment. The company discontinued Suprenza in 2016 and withdrew its FDA applications for commercial reasons, not safety concerns.
Financial and operating metrics
| Metric | FY2016 | FY2015 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $2.93 million | $1.80 million |
| General and administrative expense | $3.78 million | $0.95 million |
| Total operating expenses | $7.45 million | $3.23 million |
| Net loss | $8.30 million | $2.90 million |
| Net loss per share, basic and diluted | $0.15 | $0.09 |
| Cash used in operating activities | $5.90 million | $2.39 million |
Margins are not meaningful because the company had no revenue. At September 30, 2016, cash and cash equivalents were $294,351, working capital was negative $4.29 million, and total current liabilities were $5.18 million. The balance sheet reported $672,970 of related-party notes payable, $1.68 million of derivative warrant liability, and stockholders’ equity of $16.77 million; equity included $19.4 million of acquired in-process R&D and $1.59 million of goodwill. Accumulated deficit was $17.34 million.
Material changes versus the prior comparable period
- Net loss increased $5.39 million year over year, primarily reflecting higher G&A costs after the LMB acquisition, increased Mino-Lok development spending, and a swing in warrant revaluation from a $332,095 gain to an $838,219 loss.
- R&D expense rose by $1.14 million, including $1.91 million of Mino-Lok development costs. G&A expense rose by $2.84 million, mainly from acquisition-related compensation, consulting, corporate development, and investor-relations costs.
- The LMB acquisition was funded principally with 29.14 million Citius shares and brought Mino-Lok into the company. The company reported $5.43 million of net equity proceeds and received a $3.0 million investment from Chairman Leonard Mazur during FY2016.
- Cash declined from $676,137 to $294,351. Operating cash use increased to $5.90 million from $2.39 million.
Outlook, risks, contingencies, and unusual items
- Going concern and financing: The auditor reported substantial doubt about Citius’s ability to continue as a going concern. Management said available capital was expected to support operations for only three to six months and that additional financing was needed; the filing provides no assurance that financing would be available on acceptable terms or in time.
- Clinical outlook: Phase 3 site recruitment for Mino-Lok began in November 2016, with patient enrollment expected in the second quarter of 2017. Hydro-Lido’s reformulated product was expected to enter Phase 2b in 2017. The planned trial was estimated at 300–400 patients, costing approximately $3–5 million and taking about one year.
- Subsequent financing: After year-end, Citius launched a unit offering at a negotiated price of $0.40 per unit, with a warrant exercisable at $0.55; it sold 975,000 units for $390,000 on November 23, 2016. Related-party demand notes from Leonard Mazur totaled $1.15 million outstanding as of December 15, 2016, subject to demand and interest at prime plus 1%.
- Key risks: Neither principal development candidate was approved for marketing. Clinical failure, regulatory delays, dependence on third-party manufacturers and research organizations, competitive products, and continued need for capital could materially impair prospects. Further equity or warrant issuance could dilute existing holders.
- Controls and contingencies: Management concluded disclosure controls and internal control over financial reporting were ineffective, citing undocumented procedures, reliance on consultants for financial reporting, and inadequate segregation of duties. The company reported no material litigation. Mino-Lok licensing includes maintenance fees, sales royalties, and up to $1.05 million in regulatory and sales milestones.
- Other unusual item: The $838,219 warrant revaluation loss was a non-cash accounting charge driven in part by changes in share price and assumed volatility; warrant valuation relies on Level 3 inputs and management estimates.
Important facts for investors to verify
- Actual cash runway, subsequent financing proceeds and terms, and the timing and amount of any additional related-party borrowing.
- Mino-Lok Phase 3 protocol, enrollment progress, costs, and whether results can support FDA approval; verify the basis and limitations of the reported Phase 2b findings.
- Hydro-Lido reformulation, Phase 2b start and funding, and whether trial results demonstrate a meaningful benefit.
- Outstanding and potentially dilutive shares, options, warrants, and the status of the proposed reverse-stock-split authority.
- Remediation of material weaknesses in financial controls and any subsequent impairment assessment of acquired in-process R&D and goodwill.